Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brannagan, T.H.
Right arrow Articles by Gladstone, D.E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brannagan, T.H., III
Right arrow Articles by Gladstone, D.E.
Related Collections
Right arrow All Immunology
Right arrow All Neuromuscular Disease
Right arrow Chronic inflammatory demyelinating polyneuropathy
Right arrow Clinical trials Observational study (Cohort, Case control)

Neurology 2002;58:1856-1858
© 2002 American Academy of Neurology
Brief Communications

High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

T.H. Brannagan, III, MD, A. Pradhan, MD, T. Heiman-Patterson, MD, A.C. Winkelman, MD, M.J. Styler, MD, D.L. Topolsky, MD, P.A. Crilley, DO, R.J. Schwartzman, MD, I. Brodsky, MD and D.E. Gladstone, MD

From the Departments of Neurology (Drs. Brannagan, Heiman-Patterson, Winkelman, and Schwartzman) and Internal Medicine, Division of Hematology/Oncology (Drs. Pradhan, Styler, Topolsky, Crilley, Brodsky, and Gladstone), MCP-Hahnemann University, Philadelphia, PA.

Address correspondence and reprint requests to Dr. Thomas Brannagan, Cornell University Medical Center, 635 Madison Ave, Suite 400, New York, NY 10022; e-mail: THB2006{at}med.cornell.edu

Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.